The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Non-Hodgkin's Lymphoma Drug Market Research Report 2025
Synopsis
Non-Hodgkin's lymphoma is a type of cancer that begins in your lymphatic system, which is part of the body's germ-fighting immune system. In non-Hodgkin's lymphoma, white blood cells called lymphocytes grow abnormally and can form growths (tumors) throughout the body.
The global Non-Hodgkin's Lymphoma Drug market was valued at US$ 7891 million in 2023 and is anticipated to reach US$ 12810 million by 2030, witnessing a CAGR of 7.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Hodgkin's Lymphoma Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Hodgkin's Lymphoma Drug.
Report Scope
The Non-Hodgkin's Lymphoma Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Hodgkin's Lymphoma Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Hodgkin's Lymphoma Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Gilead Sciences
TG Therapeutics
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma
Segment by Type
Oral
Injection
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Hodgkin's Lymphoma Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Non-Hodgkin's lymphoma is a type of cancer that begins in your lymphatic system, which is part of the body's germ-fighting immune system. In non-Hodgkin's lymphoma, white blood cells called lymphocytes grow abnormally and can form growths (tumors) throughout the body.
The global Non-Hodgkin's Lymphoma Drug market was valued at US$ 7891 million in 2023 and is anticipated to reach US$ 12810 million by 2030, witnessing a CAGR of 7.2% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Non-Hodgkin's Lymphoma Drug, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Non-Hodgkin's Lymphoma Drug.
Report Scope
The Non-Hodgkin's Lymphoma Drug market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Non-Hodgkin's Lymphoma Drug market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Non-Hodgkin's Lymphoma Drug companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Roche
Gilead Sciences
TG Therapeutics
Bayer
Secura Bio
Epizyme
Eisai
Acrotech Biopharma
Teva
Eagle Pharmaceuticals
MundiPharma
Segment by Type
Oral
Injection
Segment by Application
Hospital
Retail Pharmacy
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Non-Hodgkin's Lymphoma Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Non-Hodgkin's Lymphoma Drug Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Injection
1.3 Market by Application
1.3.1 Global Non-Hodgkin's Lymphoma Drug Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Non-Hodgkin's Lymphoma Drug Market Perspective (2019-2030)
2.2 Non-Hodgkin's Lymphoma Drug Growth Trends by Region
2.2.1 Global Non-Hodgkin's Lymphoma Drug Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Non-Hodgkin's Lymphoma Drug Historic Market Size by Region (2019-2024)
2.2.3 Non-Hodgkin's Lymphoma Drug Forecasted Market Size by Region (2025-2030)
2.3 Non-Hodgkin's Lymphoma Drug Market Dynamics
2.3.1 Non-Hodgkin's Lymphoma Drug Industry Trends
2.3.2 Non-Hodgkin's Lymphoma Drug Market Drivers
2.3.3 Non-Hodgkin's Lymphoma Drug Market Challenges
2.3.4 Non-Hodgkin's Lymphoma Drug Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Non-Hodgkin's Lymphoma Drug Players by Revenue
3.1.1 Global Top Non-Hodgkin's Lymphoma Drug Players by Revenue (2019-2024)
3.1.2 Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Players (2019-2024)
3.2 Global Non-Hodgkin's Lymphoma Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Non-Hodgkin's Lymphoma Drug Revenue
3.4 Global Non-Hodgkin's Lymphoma Drug Market Concentration Ratio
3.4.1 Global Non-Hodgkin's Lymphoma Drug Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Non-Hodgkin's Lymphoma Drug Revenue in 2023
3.5 Non-Hodgkin's Lymphoma Drug Key Players Head office and Area Served
3.6 Key Players Non-Hodgkin's Lymphoma Drug Product Solution and Service
3.7 Date of Enter into Non-Hodgkin's Lymphoma Drug Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Non-Hodgkin's Lymphoma Drug Breakdown Data by Type
4.1 Global Non-Hodgkin's Lymphoma Drug Historic Market Size by Type (2019-2024)
4.2 Global Non-Hodgkin's Lymphoma Drug Forecasted Market Size by Type (2025-2030)
5 Non-Hodgkin's Lymphoma Drug Breakdown Data by Application
5.1 Global Non-Hodgkin's Lymphoma Drug Historic Market Size by Application (2019-2024)
5.2 Global Non-Hodgkin's Lymphoma Drug Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Non-Hodgkin's Lymphoma Drug Market Size (2019-2030)
6.2 North America Non-Hodgkin's Lymphoma Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Non-Hodgkin's Lymphoma Drug Market Size by Country (2019-2024)
6.4 North America Non-Hodgkin's Lymphoma Drug Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Non-Hodgkin's Lymphoma Drug Market Size (2019-2030)
7.2 Europe Non-Hodgkin's Lymphoma Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Non-Hodgkin's Lymphoma Drug Market Size by Country (2019-2024)
7.4 Europe Non-Hodgkin's Lymphoma Drug Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size (2019-2030)
8.2 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size by Region (2019-2024)
8.4 Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Non-Hodgkin's Lymphoma Drug Market Size (2019-2030)
9.2 Latin America Non-Hodgkin's Lymphoma Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Non-Hodgkin's Lymphoma Drug Market Size by Country (2019-2024)
9.4 Latin America Non-Hodgkin's Lymphoma Drug Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size (2019-2030)
10.2 Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size by Country (2019-2024)
10.4 Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Non-Hodgkin's Lymphoma Drug Introduction
11.1.4 Roche Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
11.1.5 Roche Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Non-Hodgkin's Lymphoma Drug Introduction
11.2.4 Gilead Sciences Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
11.2.5 Gilead Sciences Recent Development
11.3 TG Therapeutics
11.3.1 TG Therapeutics Company Detail
11.3.2 TG Therapeutics Business Overview
11.3.3 TG Therapeutics Non-Hodgkin's Lymphoma Drug Introduction
11.3.4 TG Therapeutics Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
11.3.5 TG Therapeutics Recent Development
11.4 Bayer
11.4.1 Bayer Company Detail
11.4.2 Bayer Business Overview
11.4.3 Bayer Non-Hodgkin's Lymphoma Drug Introduction
11.4.4 Bayer Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
11.4.5 Bayer Recent Development
11.5 Secura Bio
11.5.1 Secura Bio Company Detail
11.5.2 Secura Bio Business Overview
11.5.3 Secura Bio Non-Hodgkin's Lymphoma Drug Introduction
11.5.4 Secura Bio Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
11.5.5 Secura Bio Recent Development
11.6 Epizyme
11.6.1 Epizyme Company Detail
11.6.2 Epizyme Business Overview
11.6.3 Epizyme Non-Hodgkin's Lymphoma Drug Introduction
11.6.4 Epizyme Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
11.6.5 Epizyme Recent Development
11.7 Eisai
11.7.1 Eisai Company Detail
11.7.2 Eisai Business Overview
11.7.3 Eisai Non-Hodgkin's Lymphoma Drug Introduction
11.7.4 Eisai Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
11.7.5 Eisai Recent Development
11.8 Acrotech Biopharma
11.8.1 Acrotech Biopharma Company Detail
11.8.2 Acrotech Biopharma Business Overview
11.8.3 Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Introduction
11.8.4 Acrotech Biopharma Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
11.8.5 Acrotech Biopharma Recent Development
11.9 Teva
11.9.1 Teva Company Detail
11.9.2 Teva Business Overview
11.9.3 Teva Non-Hodgkin's Lymphoma Drug Introduction
11.9.4 Teva Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
11.9.5 Teva Recent Development
11.10 Eagle Pharmaceuticals
11.10.1 Eagle Pharmaceuticals Company Detail
11.10.2 Eagle Pharmaceuticals Business Overview
11.10.3 Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Introduction
11.10.4 Eagle Pharmaceuticals Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
11.10.5 Eagle Pharmaceuticals Recent Development
11.11 MundiPharma
11.11.1 MundiPharma Company Detail
11.11.2 MundiPharma Business Overview
11.11.3 MundiPharma Non-Hodgkin's Lymphoma Drug Introduction
11.11.4 MundiPharma Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
11.11.5 MundiPharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Non-Hodgkin's Lymphoma Drug Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Oral
Table 3. Key Players of Injection
Table 4. Global Non-Hodgkin's Lymphoma Drug Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Non-Hodgkin's Lymphoma Drug Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Non-Hodgkin's Lymphoma Drug Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Non-Hodgkin's Lymphoma Drug Market Share by Region (2019-2024)
Table 8. Global Non-Hodgkin's Lymphoma Drug Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Non-Hodgkin's Lymphoma Drug Market Share by Region (2025-2030)
Table 10. Non-Hodgkin's Lymphoma Drug Market Trends
Table 11. Non-Hodgkin's Lymphoma Drug Market Drivers
Table 12. Non-Hodgkin's Lymphoma Drug Market Challenges
Table 13. Non-Hodgkin's Lymphoma Drug Market Restraints
Table 14. Global Non-Hodgkin's Lymphoma Drug Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Non-Hodgkin's Lymphoma Drug Market Share by Players (2019-2024)
Table 16. Global Top Non-Hodgkin's Lymphoma Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin's Lymphoma Drug as of 2023)
Table 17. Ranking of Global Top Non-Hodgkin's Lymphoma Drug Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Non-Hodgkin's Lymphoma Drug Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players Non-Hodgkin's Lymphoma Drug Product Solution and Service
Table 21. Date of Enter into Non-Hodgkin's Lymphoma Drug Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Non-Hodgkin's Lymphoma Drug Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Type (2019-2024)
Table 25. Global Non-Hodgkin's Lymphoma Drug Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Type (2025-2030)
Table 27. Global Non-Hodgkin's Lymphoma Drug Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Application (2019-2024)
Table 29. Global Non-Hodgkin's Lymphoma Drug Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Non-Hodgkin's Lymphoma Drug Revenue Market Share by Application (2025-2030)
Table 31. North America Non-Hodgkin's Lymphoma Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Non-Hodgkin's Lymphoma Drug Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Non-Hodgkin's Lymphoma Drug Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Non-Hodgkin's Lymphoma Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Non-Hodgkin's Lymphoma Drug Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Non-Hodgkin's Lymphoma Drug Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Non-Hodgkin's Lymphoma Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Non-Hodgkin's Lymphoma Drug Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Non-Hodgkin's Lymphoma Drug Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size by Country (2025-2030) & (US$ Million)
Table 46. Roche Company Detail
Table 47. Roche Business Overview
Table 48. Roche Non-Hodgkin's Lymphoma Drug Product
Table 49. Roche Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024) & (US$ Million)
Table 50. Roche Recent Development
Table 51. Gilead Sciences Company Detail
Table 52. Gilead Sciences Business Overview
Table 53. Gilead Sciences Non-Hodgkin's Lymphoma Drug Product
Table 54. Gilead Sciences Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024) & (US$ Million)
Table 55. Gilead Sciences Recent Development
Table 56. TG Therapeutics Company Detail
Table 57. TG Therapeutics Business Overview
Table 58. TG Therapeutics Non-Hodgkin's Lymphoma Drug Product
Table 59. TG Therapeutics Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024) & (US$ Million)
Table 60. TG Therapeutics Recent Development
Table 61. Bayer Company Detail
Table 62. Bayer Business Overview
Table 63. Bayer Non-Hodgkin's Lymphoma Drug Product
Table 64. Bayer Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024) & (US$ Million)
Table 65. Bayer Recent Development
Table 66. Secura Bio Company Detail
Table 67. Secura Bio Business Overview
Table 68. Secura Bio Non-Hodgkin's Lymphoma Drug Product
Table 69. Secura Bio Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024) & (US$ Million)
Table 70. Secura Bio Recent Development
Table 71. Epizyme Company Detail
Table 72. Epizyme Business Overview
Table 73. Epizyme Non-Hodgkin's Lymphoma Drug Product
Table 74. Epizyme Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024) & (US$ Million)
Table 75. Epizyme Recent Development
Table 76. Eisai Company Detail
Table 77. Eisai Business Overview
Table 78. Eisai Non-Hodgkin's Lymphoma Drug Product
Table 79. Eisai Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024) & (US$ Million)
Table 80. Eisai Recent Development
Table 81. Acrotech Biopharma Company Detail
Table 82. Acrotech Biopharma Business Overview
Table 83. Acrotech Biopharma Non-Hodgkin's Lymphoma Drug Product
Table 84. Acrotech Biopharma Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024) & (US$ Million)
Table 85. Acrotech Biopharma Recent Development
Table 86. Teva Company Detail
Table 87. Teva Business Overview
Table 88. Teva Non-Hodgkin's Lymphoma Drug Product
Table 89. Teva Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024) & (US$ Million)
Table 90. Teva Recent Development
Table 91. Eagle Pharmaceuticals Company Detail
Table 92. Eagle Pharmaceuticals Business Overview
Table 93. Eagle Pharmaceuticals Non-Hodgkin's Lymphoma Drug Product
Table 94. Eagle Pharmaceuticals Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024) & (US$ Million)
Table 95. Eagle Pharmaceuticals Recent Development
Table 96. MundiPharma Company Detail
Table 97. MundiPharma Business Overview
Table 98. MundiPharma Non-Hodgkin's Lymphoma Drug Product
Table 99. MundiPharma Revenue in Non-Hodgkin's Lymphoma Drug Business (2019-2024) & (US$ Million)
Table 100. MundiPharma Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Non-Hodgkin's Lymphoma Drug Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Non-Hodgkin's Lymphoma Drug Market Share by Type: 2023 VS 2030
Figure 3. Oral Features
Figure 4. Injection Features
Figure 5. Global Non-Hodgkin's Lymphoma Drug Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global Non-Hodgkin's Lymphoma Drug Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Retail Pharmacy Case Studies
Figure 9. Other Case Studies
Figure 10. Non-Hodgkin's Lymphoma Drug Report Years Considered
Figure 11. Global Non-Hodgkin's Lymphoma Drug Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Non-Hodgkin's Lymphoma Drug Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Non-Hodgkin's Lymphoma Drug Market Share by Region: 2023 VS 2030
Figure 14. Global Non-Hodgkin's Lymphoma Drug Market Share by Players in 2023
Figure 15. Global Top Non-Hodgkin's Lymphoma Drug Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Non-Hodgkin's Lymphoma Drug as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Non-Hodgkin's Lymphoma Drug Revenue in 2023
Figure 17. North America Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Non-Hodgkin's Lymphoma Drug Market Share by Country (2019-2030)
Figure 19. United States Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Non-Hodgkin's Lymphoma Drug Market Share by Country (2019-2030)
Figure 23. Germany Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Non-Hodgkin's Lymphoma Drug Market Share by Region (2019-2030)
Figure 31. China Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Non-Hodgkin's Lymphoma Drug Market Share by Country (2019-2030)
Figure 39. Mexico Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Non-Hodgkin's Lymphoma Drug Market Share by Country (2019-2030)
Figure 43. Turkey Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Non-Hodgkin's Lymphoma Drug Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Roche Revenue Growth Rate in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
Figure 46. Gilead Sciences Revenue Growth Rate in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
Figure 47. TG Therapeutics Revenue Growth Rate in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
Figure 48. Bayer Revenue Growth Rate in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
Figure 49. Secura Bio Revenue Growth Rate in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
Figure 50. Epizyme Revenue Growth Rate in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
Figure 51. Eisai Revenue Growth Rate in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
Figure 52. Acrotech Biopharma Revenue Growth Rate in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
Figure 53. Teva Revenue Growth Rate in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
Figure 54. Eagle Pharmaceuticals Revenue Growth Rate in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
Figure 55. MundiPharma Revenue Growth Rate in Non-Hodgkin's Lymphoma Drug Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
